Asset Details
Do you wish to reserve the book?
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections
Do you wish to request the book?
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections
2017
Overview
Background
Current prevention options for upper respiratory infections (URIs) are not optimal. We conducted a randomized, double-blinded, placebo-controlled pilot clinical trial to evaluate the safety and efficacy of ARMS-I™ (currently marketed as Halo™) in the prevention of URIs.
Methods
ARMS-I is patented novel formulation for the prevention and treatment of influenza, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, CPC) and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact and invasion. Healthy adults (18–45 years of age) were randomized into ARMS-I or placebo group (50 subjects each). The drug was sprayed intra-orally (3× daily) for 75 days. The primary objectives were to establish whether ARMS-I decreased the frequency, severity or duration of URIs. Secondary objectives were to evaluate safety, tolerability, rate of virus detection, acceptability and adherence; effect on URI-associated absenteeism and medical visits; and effect of prior influenza vaccination on study outcomes.
Results
Of the 94 individuals who completed the study (placebo:
n
= 44, ARMS-I:
n
= 50), six presented with confirmed URI (placebo: 4, ARMS-I: 2), representing a 55% relative reduction, albeit this was statistically not significant). Influenza, coronavirus or rhinovirus were detected in three participants; all in the placebo group. Moreover, frequency of post-treatment exit visits was reduced by 55% in ARMS-I compared to the placebo group (
N
= 4 and 2, respectively). Fever was reported only in the placebo group. ARMS-I significantly reduced the frequency and severity of cough and sore throat, and duration of cough (
P
≤ .019 for all comparisons). ARMS-I was safe, well tolerated, had high acceptability and high adherence to medication use. Medical visits occurred only in the placebo group while absenteeism did not differ between the two arms. Prior influenza vaccination had no effect on study outcome.
Conclusions
This randomized proof-of-concept clinical trial demonstrated that ARMS-I tended to provide protection against URIs in the enrolled study participants, while reducing severity and duration of cough and sore throat. A clinical trial with a larger number of study participants is warranted.
Trial registration
ClinicalTrials.gov
NCT02644135
(retrospectively registered).
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
Subject
/ Adult
/ Anti-Infective Agents, Local - therapeutic use
/ Cetylpyridinium - therapeutic use
/ Common Cold - prevention & control
/ Consent
/ Coronavirus - isolation & purification
/ Coronavirus Infections - complications
/ Coronavirus Infections - prevention & control
/ Cough - prevention & control
/ Diaries
/ Female
/ Humans
/ Influenza Vaccines - therapeutic use
/ Influenza, Human - complications
/ Influenza, Human - prevention & control
/ Male
/ Medicine
/ Orthomyxoviridae - isolation & purification
/ Pharyngitis - prevention & control
/ Polysaccharides, Bacterial - therapeutic use
/ Respiratory tract infections
/ Respiratory Tract Infections - complications
/ Respiratory Tract Infections - prevention & control
/ Rhinovirus - isolation & purification
/ Safety
/ Testing
/ Vaccines
/ Viruses
